Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II study of PM8002 plus nab-paclitaxel in triple-negative breast cancer
CTR20221200Phase 2Active
- Sponsor
- Biotheus
- Start
- Jul 2022
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of pumitamig, paclitaxel in triple-negative breast cancer (TNBC), sponsored by Biotheus. Started Jul 2022; status: active.
02
Drugs
pumitamigpaclitaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20221200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221200.